New recommendations in the treatment of Gram-positive bacteraemia in dialysis patients

Nephrology Dialysis Transplantation

Volumn 23, Issue 1, 2008, Pages 27-32

  Ponticelli, Claudio ^a  

^a ISTITUTO AUXOLOGICO ITALIANO   (Italy)

Author keywords

Catheter associated bacteraemia; Dialysis complications; Endocarditis; Exit site infection; Gram positive infection; Peritonitis

Indexed keywords

DAPTOMYCIN; LINEZOLID; MONOAMINE OXIDASE INHIBITOR; PENICILLIN G; TEICOPLANIN; TIGECYCLINE; VANCOMYCIN; WARFARIN; ANTIINFECTIVE AGENT;

ANAPHYLAXIS; ANEMIA; ANGIONEUROTIC EDEMA; ANTIMICROBIAL THERAPY; BACTEREMIA; BONE MARROW SUPPRESSION; BULLOUS SKIN DISEASE; CATHETER INFECTION; CLINICAL ASSESSMENT; CONSTIPATION; CONTINUOUS HEMOFILTRATION; CREATINE KINASE BLOOD LEVEL; DIAGNOSTIC APPROACH ROUTE; DIARRHEA; DRUG CLEARANCE; DRUG ELIMINATION; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; ENDOCARDITIS; GRAM POSITIVE BACTERIUM; HEADACHE; HEMODIAFILTRATION; HEMODIALYSIS PATIENT; HUMAN; HYPERTENSION; INFECTION PREVENTION; KIDNEY FAILURE; LACTIC ACIDOSIS; LIVER TOXICITY; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MYOPATHY; NAUSEA; NEPHROTOXICITY; NEUTROPENIA; OTOTOXICITY; PERITONEAL DIALYSIS; PERITONITIS; PRIORITY JOURNAL; PROGNOSIS; REVIEW; RISK FACTOR; SIDE EFFECT; STAPHYLOCOCCUS AUREUS; THROMBOCYTOPENIA; URINARY TRACT INFECTION; VOMITING; ALGORITHM; BACTERIAL INFECTION; EDITORIAL; PRACTICE GUIDELINE; RENAL REPLACEMENT THERAPY;

ALGORITHMS; ANTI-BACTERIAL AGENTS; BACTEREMIA; GRAM-POSITIVE BACTERIAL INFECTIONS; HUMANS; PRACTICE GUIDELINES AS TOPIC; RENAL DIALYSIS;

EID: 44449135024     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfm679     Document Type: Review

References (71)

1. Wenzel RP, Edmond MB. Team-based prevention of catheter-related infections. N Engl J Med 2007; 355: 2781-2783
2. Chavers BM, Solid CA, Gilbertson DT et al. Infection-related hospitalization rates in pediatric versus adult patients with end-stage renal disease in the United States. J Am Soc Nephrol 2007; 18: 952-959
3. Vanholder R, Argiles A, Baurmeister U et al. Uremic toxicity: present state of the art. Int J Artif Organs 2001; 24: 695-725
4. Jaber BL. Bacterial infections in hemodialysis patients: pathogenesis and prevention. Kidney Int 2005; 67: 2508-2519
5. Koziol-Montewka M, Szczepanik A, Baranowicz I et al. The investigation of Staphylococcus aureus and coagulase-neagative staphylococci nasal carriage among patients undergoing hemodialysis. Microbiol Res 2006; 161: 281-287
6. Ponticelli C, Bencini PL. Pruritus in dialysis patients: a neglected problem. Nephrol Dial Transplant 1995; 10: 2174-2176
7. Katneni R, Hedayati SS. Central-venous catheter-related bacteremia in chronic hemodialysis patients: epidemiology and evidence-based management. Nat Nephrol 2007; 3: 256-266
8. Klouche K, Amigues L, Deleuze S et al. Complications, effects on dialysis dose, and survival of tunneled femoral dialysis catheters in acute renal failure. Am J Kidney Dis 2007; 49: 99-108
9. Duncan ND, Singh S, Cairns TD et al. Tesio-Caths provide effective and safe long-term vascular access. Nephrol Dial Transplant 2004; 19: 2816-2822
10. Di Iorio BR, Mondillo F, Bortone S et al. Fourteen years of hemodialysis with a central venous catheter: mechanical long-term complications. J Vasc Access 2006; 7: 60-65
11. Troidle L, Eisen T, Pacelli L et al. Complications associated with the development of bacteremia with Staphylococcus aureus. Hemodial Int 2007; 11: 72-75
12. Melanoski GJ, Samore MH, Pefanis A et al. Staphylococcus aureus catheter-associated bacteremia. Minimal effective therapy and unusual infectious complications associated with arterial sheath catheters. Arch Intern Med 1995; 155: 1161-1166
13. Centers for Disease Control and Prevention (CDC). Invasive methicillin-resistant Staphylococcus aureus infections among dialysis patients - United States 2005. MMWR Morb Mortal Wkly Rep 2007; 56: 197-199
14. Jacobsson G, Dashti S, Wahlberg T et al. The epidemiology of and risk factors for invasive Staphylococcus aureus infections in western Sweden. Scand J Infect Dis 2007; 39: 6-13
15. Hoen B, Paul-Dauphin A, Hestin D et al. EPIBACDIAL: amulticenter prospective study of risk factors for bacteremia in chronic hemodialysis patients. J Am Soc Nephrol 1998; 9: 869-876
16. Bender FH, Bernardini J, Piraino B. Prevention of infectious complications in peritoneal dialysis: best demonstrated practices. Kidney Int Suppl 2006; 103: S44-S54
17. Wadhwa NK, Reddy GH. Exit-site care in peritoneal dialysis. Contrib Nephrol 2007; 154: 117-124
18. De Vecchi A, Corciulo R, Salomone M et al. Catheter-related interventions to prevent peritonitis in peritoneal dialysis: guideline from the Italian Society of Nephrology. G Ital Nefrol 2007; 24(Suppl 37): 136-148
19. Piraino B. Staphylococcus aureus infections in dialysis patients: focus on prevention. ASAIO J 2000; 46: S13-S17
20. Sedlacek M, Gemery JM, Cheung AL et al. Aspirin treatment is associated with a significantly decreased risk of Staphylococcus aureus bacteremia in hemodialysis patients with tunnelled catheters. Am J Kidney Dis 2007; 49: 401-408
21. Al-Kwiesch AK, Abdul-Rahman IS. Successful prevention of tunneled central catheter infection by antibiotic lock therapy using vancomycin and gentamycin. Saudi J Kidney Dis Transplant 2007; 18: 239-247
22. Lentino JR, Baddour LM, Wray M et al. Staphylococcus aureus and other bacteremias in hemodialysis patients: antibiotic therapy and surgical removal of access site. Infection 2000; 28: 355-360
23. Kamalakannan D, Pai RM, Johnson LB et al. Epidemiology and clinical outcomes of infective endocarditis in hemodialysis patients. Ann Thorac Surg 2007; 83: 2081-2086
24. Mokrzycki MH, Singhal A. Cost-effectiveness of three strategies of managing tunnelled, cuffed haemodialysis catheters in clinically mild or asymptomatic bacteraemias. Nephrol Dial Transplant 2002; 17: 2196-2203
25. Mokrzycki MH, Zhang M, Cohen H et al. Tunnelled haemodialysis catheter bacteraemia: risk factors for bacteraemia recurrence, infectious complications and mortality. Nephrol Dial Transplant 2006; 21: 1024-1031
26. Gomez J, Garcia-Vazquez E, Banos R et al. Methicillin susceptible Staphylococcus aureus bacteremia: epidemiology and prognostic factors. A prospective study 2000-2003. Rev Clin Esp 2007; 207: 57-63
27. Jevons MP. 'Celbenin'-resistant staphylococci. Br Med J 1961; 1: 124-125
28. Centers for Disease Control and Prevention. National nosocomial infections surveillance system report, data summary from January 1992 to June 2002. Am J Infect Control 2002; 30: 458-475
29. Fridhin SK. Antimicrobial resistance in intensive care units. Clin Chest Med 2002; 20: 303-316
30. Woodford N. Biological counterstrike: antibiotic resistance mechanisms of Gram positive cocci. Clin Microbiol Infect 2005; 11(Suppl 3): 2-21
31. Begg EJ, Barclay ML, Kirkpatrick CM. The therapeutic monitoring of antimicrobial agents. Br J Clin Pharmacol 2001; 52(Suppl 1): 35S-43S
32. Gilliland KK, Flores PA, Gordon SM. Vancomycin resistant Staph: epidemiology and therapeutic options. Infect Med 2000; 17: 289-298
33. Centers for Disease Control and Prevention. Vancomycin-resistant Staphylococcus aureus-Pennsylvania 2002. MMWR Morb Mortal Wkly Rep 2002; 51: 565-567
34. Gin AS, Zhanel GG. Vancomycin-resistant enterococci. Ann Pharmacother 1996; 30: 615-624
35. Hiramatsu K. Vancomycin-resistant Staphylococcus aureus : a new model of antibiotic resistance. Lancet Infect Dis 2004; 10: 855-857
36. Cui L, Murakami H, Kuwahara-Arai K et al. Contribution of a thickened cell wall and its nonamidated component to the vancomycin resistance expressed by Staphylococcus aureus Mu 50. Antimicrob Agents Chemother 2000; 44: 2276-2285
37. Roberts MC, Sutcliffe J, Courvalin P et al. Nomenclature for macrolide and macrolide-lincosamide-streptogramin B resistance determinants. Antimicrob Agents Chemother 1999; 43(12): 2823-2830
38. Bozdogan B, Leclercq R. Effects of genes encoding resistance to streptogramins A and B on the activity of quinupristin-dalfopristin against Enterococcus faecium. Antimicrob Agents Chemother 1999; 43: 2720-2725
39. Centers for Disease Control and Prevention. Antimicrobial Resistance: A Growing Threat to Public Health. Atlanta, GA: Centers for Disease Control and Prevention, 2002
40. Hancock RE. Mechanisms of action of newer antibiotics for Gram-positive pathogens. Lancet Infect Dis 2005; 4: 209-218
41. Lin YH, Wu VC, Tsai IJ et al. High frequency of linezolid-associated thrombocytopenia among patients with renal insufficiency. Int J Antimicrob Agents 2006; 28: 345-351
42. Wu VC, Wang YT, Wang CY et al. High frequency of linezolid-associated thrombocytopenia and anemia among patients with end stage renal disease. Clin Infect Dis 2006; 42: 66-72
43. Falagas ME, Siempos II, Papagelopoulos PJ et al. Linezolid for the treatment of adults with bone and joint infections. Int J Antimicrob Agents 2007; 29: 233-239
44. Carson J, Cerda J, Chae JH et al. Severe lactic acidosis associated with linezolid use in a patient with the mitochondrial DNA A2706G polymorphism. Pharmacotherapy 2007; 27: 771-774
45. Stalker DJ, Jungbluth GL. Clinical pharmacokinetics of linezolid, a novel oxazolidinone antibacterial. Clin Pharmacokinet 2003; 42: 1129-1140
46. Fiaccadori E, Maggiore U, Rotelli C et al. Does haemodialysis significantly affect serum linezolid concentrations in critically ill patients with renal failure? A pilot investigation. Nephrol Dial Transplant 2006; 21: 1402-1406
47. Brier ME, Stalker DJ, Aronoff GR et al. Pharmacokinetics of Linezolid in subjects with renal dysfunction. Antimicrob Agents Chemother 2003; 47: 2775-2780
48. Mauro IS, Peloquin CA, Schmude K et al. Clearance of linezolid via continuous venovenous hemodiafiltration. Am J Kidney Dis 2006; 47: e83-e86
49. Cieloszyk K, Amodio-Groton M, Saeed M et al. Linezolid resistance in three isolates of coagulase-negative staphylococci. Ann Pharmacother 2007; 4: 526-527
50. Toh SM, Xiong L, Arias CA et al. Acquisition of a natural resistance gene renders a clinical strain of methicillin-resistant Staphylococcus aureus resistant to the synthetic antibiotic linezolid. Mol Microbiol 2007; 64: 1506-1514
51. Zhanel GG, Homenuik K, Nichol K et al. The glycylcyclines: a comparative review with the tetracyclines. Drugs 2004; 64: 63-88
52. Doan TL, Fung HB, Mehta D et al. Tigecycline: a glycylcycline antimicrobial agent. Clin Ther 2006; 8: 1079-1106
53. Rello J. Pharmacokinetics, pharmacodynamics, safety and tolerability of tigecycline. J Chemother 2005; (Suppl 1): 12-22
54. Van Wart SA, Cirincione BB, Ludwig EA et al. Population pharmacokinetics of tigecycline in healthy volunteers. J Clin Pharmacol 2007; 47: 727-737
55. Meagher AK, Ambrose PG, Grasela TH et al. The pharmacokinetic and pharmacodynamic profile of tigecycline. Clin Infect Dis 2005; 41(Suppl 5): S333-S340
56. Stein GE, Craig WA. Tigecycline: a critical analysis. Clin Infect Dis 2006; 43: 518-524
57. Carpenter CF, Chambers HF. Daptomycin: another novel agent for treating infections due to drug-resistant Gram-positive pathogens. Clin Infect Dis 2004; 38: 994-1000
58. Silverman JA, Perlmutter NG, Shapiro HM. Correlation of daptomycin bactericidal activity and membrane depolarization in Staphylococcus aureus. Antimicrob Agents Chemother 2003; 47: 2538-2544
59. Fuchs PC, Barry AL, Brown SD. In vitro bactericidal activity of daptomycin against staphylococci. J Antimicrob Chemother 2002; 49: 467-470
60. Oleson FB , Berman CL, Kirkpatrick JB et al. Once-daily dosing in dogs optimizes daptomycin safety. Antimicrob Agents Chemother 2000; 44: 2948-2953
61. Kaatz GW, Lundstrom TS, Seo SM. Mechanisms of daptomycin resistance in Staphylococcus aureus. Int J Antimicrob Agents 2006; 28: 280-287
62. Fowler VG , Boucher HW, Corey GR et al. S. aureus Endocarditis and Bacteremia Study Group daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus. N Engl J Med 2006; 355: 653-665
63. Martone WJ, Lamp KC. Efficacy of daptomycin in complicated skin and skin-structure infections due to methicillin-sensitive and -resistant Staphylococcus aureus: results from the CORE Registry. Curr Med Res Opin 2006; 22(12): 2337-2343
64. Garau J. Management of cSSTIs: the role of daptomycin. Curr Med Res Opin 2006; 22: 2079-2087
65. Papadopoulos S, Ball AM, Liewer SE et al. Rhabdomyolysis during therapy with daptomycin. Clin Infect Dis 2006; 42: e108-e110
66. Kazory A, Dibadj K, Weiner ID. Rhabdomyolysis and acute renal failure in a patient treated with daptomycin. J Antimicrob Chemother 2006; 57: 578-579
67. Dvorchik B, Arbeit RD, Chung J et al. Population pharmacokinetics of daptomycin. Antimicrob Agents Chemother 2004; 48: 2799-2807
68. Hermsen ED, Hovde LB, Hotchkiss JR et al. Increased killing of staphylococci and streptococci by daptomycin compared with cefazolin and vancomycin in an in vitro peritoneal dialysate model. Antimicrob Agents Chemother 2003; 47: 3764-3767
69. Churchwell MD, Pasko DA, Mueller BA. Daptomycin clearance during modeled continuous renal replacement therapy. Blood Purif 2006; 24: 548-554
70. Raad I, Hanna H, Jiang Y et al. Comparative activities of daptomycin, linezolid, and tigecycline against catheter-related methicillin-resistant Staphylococcus bacteremic isolates embedded in biofilm. Antimicrob Agents Chemother 2007; 51: 1656-1660
71. Khardori N. Antibiotics - past, present, and future. Med Clin N Am 2006; 90: 1049-1076